From burden to action: Saudi Arabia's strategy on antimicrobial resistance.

IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Open Medicine Pub Date : 2026-04-27 eCollection Date: 2026-01-01 DOI:10.1515/med-2026-1380
Shuaibu Abdullahi Hudu, Abdulgafar Olayiwola Jimoh
{"title":"From burden to action: Saudi Arabia's strategy on antimicrobial resistance.","authors":"Shuaibu Abdullahi Hudu, Abdulgafar Olayiwola Jimoh","doi":"10.1515/med-2026-1380","DOIUrl":null,"url":null,"abstract":"<p><p>Antimicrobial Resistance (AMR) is a significant public health challenge in Saudi Arabia and globally. This review consolidates evidence on the burden, drivers, policy responses, and progress in controlling AMR from 2010 to 2025 across human health, animal health, and the environment. The burden is substantial, especially from multidrug-resistant strains such as ESBL-producing Enterobacteriaceae, carbapenem-resistant <i>Klebsiella pneumoniae</i>, and methicillin-resistant <i>Staphylococcus aureus</i>. Factors contributing to this include antibiotic misuse, over-the-counter availability, mass gatherings, insufficient infection control, and agricultural use. Saudi Arabia has made progress through a One Health-oriented National Action Plan (2017, renewed 2022-2025), antimicrobial stewardship programs, surveillance efforts, and stricter regulations. However, challenges remain in community surveillance, laboratory capacity, and behavioral change. As indicated by key stakeholders, further efforts to expand stewardship, improve diagnostics, regulate antibiotic sales, and implement AI-driven surveillance are essential next steps. Increased investment in research, innovation, and partnerships can position Saudi Arabia as a leader in regional AMR containment initiatives.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"21 1","pages":"20261380"},"PeriodicalIF":1.6000,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124018/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2026-1380","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Antimicrobial Resistance (AMR) is a significant public health challenge in Saudi Arabia and globally. This review consolidates evidence on the burden, drivers, policy responses, and progress in controlling AMR from 2010 to 2025 across human health, animal health, and the environment. The burden is substantial, especially from multidrug-resistant strains such as ESBL-producing Enterobacteriaceae, carbapenem-resistant Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus. Factors contributing to this include antibiotic misuse, over-the-counter availability, mass gatherings, insufficient infection control, and agricultural use. Saudi Arabia has made progress through a One Health-oriented National Action Plan (2017, renewed 2022-2025), antimicrobial stewardship programs, surveillance efforts, and stricter regulations. However, challenges remain in community surveillance, laboratory capacity, and behavioral change. As indicated by key stakeholders, further efforts to expand stewardship, improve diagnostics, regulate antibiotic sales, and implement AI-driven surveillance are essential next steps. Increased investment in research, innovation, and partnerships can position Saudi Arabia as a leader in regional AMR containment initiatives.

从负担到行动:沙特阿拉伯抗微生物药物耐药性战略。
抗微生物药物耐药性(AMR)是沙特阿拉伯和全球面临的一项重大公共卫生挑战。本综述综合了2010年至2025年在人类健康、动物健康和环境方面控制抗生素耐药性的负担、驱动因素、政策应对和进展方面的证据。负担是巨大的,特别是来自多重耐药菌株,如产生esbl的肠杆菌科,耐碳青霉烯的肺炎克雷伯菌和耐甲氧西林的金黄色葡萄球菌。造成这种情况的因素包括抗生素滥用、非处方药、大规模集会、感染控制不足和农业使用。沙特阿拉伯通过“一个健康导向的国家行动计划”(2017年,更新为2022-2025年)、抗菌药物管理规划、监测工作和更严格的法规取得了进展。然而,在社区监测、实验室能力和行为改变方面仍然存在挑战。正如主要利益攸关方所指出的,下一步必须进一步努力扩大管理、改善诊断、规范抗生素销售和实施人工智能驱动的监测。增加对研究、创新和伙伴关系的投资,可以使沙特阿拉伯成为区域抗微生物药物耐药性遏制举措的领导者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Open Medicine
Open Medicine Medicine-General Medicine
CiteScore
3.00
自引率
0.00%
发文量
153
审稿时长
20 weeks
期刊介绍: Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书